Trials / Active Not Recruiting
Active Not RecruitingNCT05023551
Study of DSP-0390 in Patients With Recurrent High-Grade Glioma
A Phase 1 Study of DSP-0390 in Patients With Recurrent High-Grade Glioma
- Status
- Active Not Recruiting
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 39 (estimated)
- Sponsor
- Sumitomo Pharma America, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a study of DSP-0390 in patients with recurrent high grade glioma.
Detailed description
This study will evaluate the safety and efficacy of DSP-0390 in patients with recurrent high grade glioma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DSP-0390 | DSP-0390 administered orally |
Timeline
- Start date
- 2021-09-08
- Primary completion
- 2026-09-30
- Completion
- 2026-10-31
- First posted
- 2021-08-26
- Last updated
- 2025-09-16
Locations
9 sites across 2 countries: United States, Japan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05023551. Inclusion in this directory is not an endorsement.